Who
Natarajan Sethuraman
President, Research & Develop.
Company insider
Files Form 4 as: President, Research & Develop., Entrada Therapeutics.
In numbers
- Trades disclosed
- 59
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $2.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 28 Oct 2021
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $15K2,079 at $7.14 | filing |
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $15K2,079 at $7.14 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $399K25,907 at $15.39 | filing |
| 4 May 2026filed 4 May 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $399K25,907 at $15.39 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $89K7,577 at $11.76 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $89K7,577 at $11.76 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $45K3,898 at $11.66 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $45K3,898 at $11.66 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —55,800 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,200 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,200 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —55,800 at $0.00 | filing |
| 2 Sep 2025filed 4 Sep 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,5571,760 at $5.43 | filing |
| 3 Mar 2025filed 4 Mar 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $72K6,138 at $11.68 | filing |
| 1 Mar 2025filed 4 Mar 2025 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,800 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,800 at $0.00 | filing |
| 3 Dec 2024filed 3 Dec 2024 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $236K11,703 at $20.15 | filing |
| 2 Dec 2024filed 3 Dec 2024 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $83K4,088 at $20.26 | filing |
| 29 Nov 2024filed 3 Dec 2024 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,000100 at $20.00 | filing |
| 13 Nov 2024filed 13 Nov 2024 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K2,700 at $20.04 | filing |
News
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Natarajan Sethuraman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.